Non Cme Dinner

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Regeneron.

15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 9, 2019

InterContinental New York Times Square

300 W 44th St.
New York, NY 10036


click to View Brochure and Agenda

PER’s 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a 1-day educational conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with melanoma and other cutaneous malignancies.

Led by world-renowned experts Jeffrey S. Weber, MD, PhD, and Omid Hamid, MD, this international symposium, now in its 15th year, will provide physicians with the tools they need to personalize care for every patient they treat. Sessions will include presentations on advances in immunotherapy, the latest on targeted therapies, the benefits of regional therapy, how to use predictive and prognostic modeling, how to manage treatment-related adverse events associated with emerging strategies, and more! This year’s symposium will once again feature the dynamic and interactive Medical Crossfire® format, where experts will engage in a rigorous debate to answer your questions, and reach consensus on ongoing paradigm shifts. This fast-paced and interactive forum will once again prove highly practical to physicians who treat patients with skin cancer and provide them with unmatched access to the leading experts. Join us in New York, and together, we’ll meet the challenges currently facing the field!

What you will learn at the International Symposium on Melanoma!

  • The latest strategies on checkpoint inhibitor strategies, when to use single-agent or combination regiments
  • Insights into the role of other immunotherapy targets including OX40, GITR, IDO, and more
  • Current and emerging combinations to treat BRAF-mutant melanoma
  • Expert perspectives on the management of regional disease and how to prevent recurrence
  • Evolving strategies to mitigate treatment-related toxicities with targeted and immunotherapies

Benefits of Attending

  • Interact with the Expert Faculty and Colleagues
  • Integrate Recent Data into Your Practice Tomorrow!
  • Learn how immunotherapy combinations will change your practice
  • Update your strategies to mitigate treatment-related toxicities
  • Consult with melanoma and other cutaneous disease experts
  • Expand your network of colleagues and peers

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Regeneron.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Discuss the latest clinical trial evidence on current and emerging treatment strategies across cutaneous malignancies, including regional, immuno-, and targeted therapies
  • Demonstrate the impact of multidisciplinary approaches for the identification and management of treatment-related toxicities in patients with cutaneous malignancies
  • Detail the evolving use of biomarkers and other methods to personalize care across treatment settings for patients with melanoma and other cutaneous malignancies
  • Place recent and emerging trial evidence in the context of changing treatment paradigms in order to optimally sequence therapies in the management of melanoma, basal cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies

Program Co-Chairs

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute
Director of Experimental Therapeutics, Cedars Sinai Medical Care Foundation
Los Angeles, CA


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Calendar of Events
Filter By